News and press releases covering LASEROPTEK devices and technology are available in this corner.

Keep up to date with our global presence in the medical and aesthetics here.

LASEROPTEK Receives PMDA Approval for PALLAS™

SEOUL, Republic of Korea – January 6, 2021 – LASEROPTEK Co., Ltd. has announced PMDA approval for its PALLAS™ laser system. The PMDA, or Pharmaceuticals and Medical Devices Agency, is a pharmaceutical regulatory authority in Japan renowned for its strict licensing procedures.

With that, PALLAS is the first-ever Korean device to be approved by the PMDA for treating chronic skin conditions including vitiligo, psoriasis, and atopic dermatitis.

Most recently, LASEROPTEK’s PicoLO, HELIOS III, and LOTUS III laser systems also obtained licensing from Australia’s own regulatory body for medicines, medical devices, and diagnostics, the
Therapeutic Good Administration (TGA).

PALLAS is the world’s first solid-state Nd:YAG laser system that integrates 308nm and 311nm wavelengths designed to treat such conditions both effectively and safely – without the use of anesthetics – for people of all ages. PALLAS also reduces the cost of maintenance for users while operating the device daily.

Following PMDA approval of PALLAS, C.J. Lee, CEO of LASEROPTEK, said the company is confident it can accelerate entry into global medical and aesthetic markets with cutting-edge laser
systems supported by strong roots in R&D, and firm establishment of the company’s global network infrastructure.

The clinical efficacies of PALLAS are featured in the Journal of American Medical Association (JAMA) Dermatology, Journal of the American Academy of Dermatology (JAAD), Wiley’s
Photodermatology, Photoimmunology & Photomedicine, among other prestigious publications.

About LASEROPTEK Co., Ltd.
LASEROTPEK is a global developer and manufacturer of aesthetic and medical laser systems. Founded in 2000 with in-house R&D capabilities, LASEROPTEK offers safe, stable, and high-quality
laser systems merging together advanced laser technologies with clinical efficacy.

To learn more about PALLAS and the entire lineup of LASEROPTEK lasers, please visit us at or email us at